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Abstract
There have been considerable recent advances in understanding the genetic architecture of Tourette Syndrome (TS) as
well as its underlying neurocircuitry. However, the mechanisms by which genetic variation that increases risk for TS—
and its main symptom dimensions—influence relevant brain regions are poorly understood. Here we undertook a
genome-wide investigation of the overlap between TS genetic risk and genetic influences on the volume of specific
subcortical brain structures that have been implicated in TS. We obtained summary statistics for the most recent TS
genome-wide association study (GWAS) from the TS Psychiatric Genomics Consortium Working Group (4644 cases and
8695 controls) and GWAS of subcortical volumes from the ENIGMA consortium (30,717 individuals). We also undertook
analyses using GWAS summary statistics of key symptom factors in TS, namely social disinhibition and symmetry
behaviour. SNP effect concordance analysis (SECA) was used to examine genetic pleiotropy—the same SNP affecting
two traits—and concordance—the agreement in single nucelotide polymorphism (SNP) effect directions across these
two traits. In addition, a conditional false discovery rate (FDR) analysis was performed, conditioning the TS risk variants
on each of the seven subcortical and the intracranial brain volume GWAS. Linkage disequilibrium score regression
(LDSR) was used as validation of the SECA method. SECA revealed significant pleiotropy between TS and putamen (p=
2 × 10−4) and caudate (p= 4 × 10−4) volumes, independent of direction of effect, and significant concordance between
TS and lower thalamic volume (p= 1 × 10−3). LDSR lent additional support for the association between TS and
thalamus volume (p= 5.85 × 10−2). Furthermore, SECA revealed significant evidence of concordance between the
social disinhibition symptom dimension and lower thalamus volume (p= 1 × 10−3), as well as concordance between
symmetry behaviour and greater putamen volume (p= 7 × 10−4). Conditional FDR analysis further revealed novel
variants significantly associated with TS (p < 8 × 10−7) when conditioning on intracranial (rs2708146, q= 0.046; and
rs72853320, q= 0.035) and hippocampal (rs1922786, q= 0.001) volumes, respectively. These data indicate concordance
for genetic variation involved in disorder risk and subcortical brain volumes in TS. Further work with larger samples is
needed to fully delineate the genetic architecture of these disorders and their underlying neurocircuitry.
Introduction
Tourette’s Syndrome (TS) has a global prevalence of
~0.85–1%1 and is characterised by repetitive motor and
phonic tics, with onset typically before the age of 18
years2. TS has one of the highest heritability estimates for
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neuropsychiatric disorders (70–80%)3, with 50–60% of
this heritability directly attributable to single nucleotide
polymorphisms (SNPs)4. In recent years, there have been
significant advances in understanding the genetic archi-
tecture of TS and in delineating other aspects of its
underlying neurobiology, including its specific
neuroanatomy1.
The Psychiatric Genomics Consortium Tourette Syn-
drome working group (PGC-TS) undertook the first
genome-wide association study (GWAS) of TS, compris-
ing 1285 cases and 4964 controls5. While no SNP reached
genome-wide significance, the top-ranking variants were
enriched for genes that affect gene expression and
methylation levels in the fronto-striatal circuitry, con-
sistent with contemporary models of TS6. The lack of
genome-wide significance at this sample size likely reflects
the polygenic and heterogeneous nature of TS7–9, which is
further complicated by comorbidity with other psychiatric
disorders, such as obsessive-compulsive disorder (OCD),
autism spectrum disorders (ASD) and attention-deficit/
hyperactivity disorder (ADHD)10. Another study used the
most highly associated variants from the PGC-TS GWAS
to predict TS status (p= 0.042) in an independent cohort
(609 cases and 610 controls) and they accounted for 0.52%
of the variance observed between cases and controls11.
Several studies have attempted to clarify the complex
nature of TS by identifying more homogenous endophe-
notypes and symptom dimensions12–15. While these stu-
dies identified several classes of Tourette-related
endophenotypes using multivariate methods, all were
based on relatively small samples (n < 1000)13–15. A recent
and considerably larger analysis of individuals with TS
and their family members that assessed not only TS, but
also OCD and ADHD (ntotal= 3494), identified two cross-
disorder symptom dimensions, namely social disinhibi-
tion and symmetry behaviour16. Social disinhibition
includes uttering syllables/words, echolalia/palilalia,
coprolalia/copropraxia, and obsessive urges to offend/
mutilate/be destructive. Symmetry behaviour includes
symmetry, evening up, checking obsessions, ordering,
arranging, counting, writing-rewriting compulsions and
repetitive writing tics. Social disinhibition (h2= 0.35 ±
0.03) was associated with OCD polygenic risk scores (PRS;
p= 0.02) and less strongly with TS and ADHD PRS,
which did not meet statistical significance (p= 0.11 and
p= 0.10, respectively). In contrast, symmetry behaviour
(h2= 0.39 ± 0.03) was significantly correlated with TS PRS
(p= 0.02) and not with OCD and ADHD (p= 0.18 and
p= 0.26, respectively).
There have also been noteworthy advances in the
understanding of the neuronal circuitry of TS. The role of
the cortico-striatal-thalamo-cortical circuits (CSTC) in
TS has been emphasized17, although data on changes in
the volume and function of specific brain regions in the
CSTC in individuals with TS is less consistent. Lower
bilateral nucleus caudate volumes18,19, inferior occipital
volumes20, prefrontal cortex volumes20,21, corpus callo-
sum volumes and decreased white matter connectivity22,23
have been observed in children with TS. Greater grey
matter volumes have also been observed in the thala-
mus21,24, hypothalamus and midbrain among children
and adults with TS21,25. Amygdalar volume has been
reported to be greater in children and lower in
adulthood25.
Little work to date has, however, focused on pleiotropy
or concordance of genetic risk for TS, and genetic variants
that influence subcortical brain volume. Pleiotropy refers
to a SNP that affects both phenotypes, regardless of
whether the effect direction is the same for both. Con-
cordance, however, requires that the SNP has the same
direction of effect for both phenotypes. The Enhancing
Neuroimaging Genetics through Meta-analysis
(ENIGMA) consortium recently performed a GWAS of
structural brain MRI scans of 30,717 individuals26. The
ENIGMA subcortical brain volumes study identified novel
genetic variants associated with the volumes of the
putamen and caudate nucleus26 and subsequently detec-
ted an overlap with OCD risk variants27. ENIGMA pro-
vides an opportunity to examine the relationship between
GWAS data in TS with the genetic contributions to
regional brain volumes. Here we aim to assess genetic
concordance for TS and specific symptom profiles (i.e.,
social disinhibition and symmetry behaviour) with the
volume of relevant subcortical and intracranial brain
regions. We used summary statistics from the ENIGMA
subcortical and intracranial brain volumes GWAS26 and
the most recent PGC-TS GWAS5.
Methods
Description of original association studies
We obtained summary statistics of adult European
ancestry participants (4644 cases and 8695 controls) and
9,076,550 SNPs from the most recent PGC-TS GWAS5,
including unpublished data. Approximately half of this
cohort also had either comorbid OCD or ADHD. A subset
of cases had information regarding symmetry behaviour
(n= 1419) and social disinhibition (n= 1414) symptom
classes. Participants were diagnosed using the DSM-IV-
TR28 by trained clinicians. In addition, we used GWAS
summary statistics from the ENIGMA Consortium meta-
analysis of subcortical brain volumes across 50 cohorts,
including MRI scans of 30,717 individuals and 9,702,043
SNPs26. This cohort consisted of healthy controls (79%) as
well as patients (21%) diagnosed with neuropsychiatric
disorders (including anxiety disorders, Alzheimer’s dis-
ease, ADHD, major depression, bipolar disorder, epilepsy
and schizophrenia). A direct comparison of the GWAS
summary statistics between the full ENIGMA results
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(including patients) and a subset of ENIGMA results
(excluding patients) showed that they were very highly
correlated (Pearson’s r > 0.99) for all brain traits26. Prior to
the analyses here, we verified that there was no cohort
overlap between the TS and brain volume GWASs and
therefore individual overlap was likely to be minimal, if
any at all. The brain volume GWAS data comprised
GWASs of seven subcortical brain volumes (nucleus
accumbens, amygdala, caudate nucleus, hippocampus,
globus pallidus, putamen, thalamus) and total intracranial
volume (ICV). GWAS test statistics were genome-
controlled to adjust for spurious inflation factors. All
cohort studies were approved by a local ethics board prior
to subject recruitment and all subjects gave written,
informed consent before participating.
Post-processing of genetic data
To statistically compare the TS and brain volume
GWASs, we used the 7,682,991 SNPs that passed quality
control and filtering rules in all datasets. With these data,
we performed a clumping procedure in PLINK29 to
identify an independent SNP from every linkage dis-
equilibrium (LD) block across the genome. The clumping
procedure was performed separately for each of the eight
brain volume GWASs using a 500 kb window, with SNPs
in LD (r2 > 0.2), in the European reference samples from
the 1000 Genome Project (Phase 1, version 3). The SNP
with the lowest p-value within each LD block was selected
as the index SNP representing that LD block and all other
SNPs in the LD block were dropped from the analysis.
The result, after applying the clumping procedure, was a
total of eight independent sets of SNPs representing the
total variation explained across the genome, conditioned
on the significance in each brain volume GWAS. For each
of these eight sets of SNPs, we then determined the cor-
responding TS GWAS test statistic for each independent
index SNP and used these datasets for the subsequent
analyses.
Tests of pleiotropy and concordance
We used SNP effect concordance analysis (SECA)30 (see
Nyholt 2014 for details of the SECA analysis) to test for
genetic pleiotropy—the same SNP affecting two traits—
and concordance—the agreement in SNP effect directions
across these two traits—between TS, social disinhibition
or symmetry behaviour and all seven subcortical struc-
tures and ICV.
Conditional false discovery rate to detect TS, social
disinhibition or symmetry behaviour risk variants
We also examined if conditioning the results of the TS
GWAS on genetic variants that influence subcortical
brain volume (TS | subcortical brain volume) could
improve our ability to detect variants associated with
TS31,32. At this sample size, the analyses were under-
powered to investigate the symptom dimensions sepa-
rately. For a given brain volume phenotype, we selected
subsets of SNPs at 14 false discovery rate (FDR) thresh-
olds (q-values ≤ 1 × 10−5, 1 × 10−4, 1 × 10−3, 0.01, 0.1, 0.2,
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1) and looked up the cor-
responding p-values for each SNP subset in the TS GWAS
and the social disinhibition and symmetry behaviour
symptom clusters. Next, we applied the FDR method33 to
each subset of p-values in the TS GWAS and the social
disinhibition and symmetry behaviour symptom clusters.
Individual SNPs were considered significant if the p-value
was lower than the significance threshold, allowing for an
FDR of 5%, conditioned on any subset of SNPs from the
brain volume GWASs. The LD-pruned data were required
for the conditional FDR SNP analysis because regions
with varying amounts of SNPs within an LD block can
affect the ranking and re-ranking of SNPs under the
conditional models. However, the chosen SNP included in
the model is likely just a “proxy” for SNPs in the LD block
and should not necessarily be considered a causal variant
or even the most significant SNP in terms of its overlap
between traits.
Stratified true discovery rate (TDR) plots were con-
structed by subsetting SNPs based on associations with a
secondary trait (i.e. subcortical brain volumes), and gen-
erating TDR plots separately for each subset of SNPs
based on their association with the main trait of interest
(i.e. TS). The SNPs that had reached at least marginal
significance thresholds for the relevant subcortical brain
regions were selected for inclusion in the plots. The
selected p-value thresholds were 1.0, 0.1, 0.01 and 0.001,
which were log-transformed. A conservative measure of
TDR is calculated for each SNP as 1 – (p/q), where p
represents the p-value of a SNP’s association with the
primary trait of interest (TS), and q represents the
empirical conditional cumulative distribution function q
(TS | subcortical brain region)34.
Estimating genetic correlation using LD score regression
In order to replicate significant findings from our pri-
mary analysis with SECA, we used an alternative method,
LD score regression (LDSR), which estimates a genetic
correlation between two trait pairs based on the GWAS
summary statistics of each trait analysed separately35,36.
LDSR estimates a genetic correlation with a fitted linear
model of Z-scores obtained from the product of sig-
nificance statistics for each SNP in a given set of GWAS
results compared to the level of linkage disequilibrium at
a given SNP. SNPs in high LD are expected to have high
Z-scores in polygenic traits with common genetic over-
lap35. We used the ldsc program (https://github.com/
bulik/ldsc) to perform LDSR following the methods out-
lined in Bulik-Sullivan et al., 201536. LDSR was
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underpowered at this sample size to analyse the amygdala,
as well as the TS symptom clusters. Therefore, LDSR was
only used to test for an association with the broader TS
phenotype and the remaining seven brain regions of
interest. Given the number of tests performed, we set a
Bonferroni corrected significance level at p*= 0.05/48=
1.042 × 10−3 to account for the three traits tested (TS,
social disinhibition and symmetry behaviour), the eight
brain volumes and the two tests performed (SECA
and LDSR).
Results
Evidence for pleiotropy between brain volume and TS and
related symptom cluster risk variants
We found significant evidence of global pleiotropy—
same SNP, regardless of effect direction—between var-
iants that infer risk for the broader TS phenotype and
variants that are associated with lower putamen (Table 1,
p= 2 × 10−4) and caudate volumes (Table 1, p= 4 ×
10−4). Further, we found nominally significant (p < 0.05)
evidence of pleiotropy between TS risk variants and var-
iants associated with lower ICV, accumbens, pallidum,
and thalamus volumes and greater hippocampus volume
(Table 1). No evidence for global pleiotropy was found for
either the social disinhibition (Table 2) or symmetry
behaviour (Table 3) symptom clusters.
Evidence for concordance between brain volumes and TS
and related symptom clusters risk variants
We found significant evidence of negative concordance—
same SNP, same direction of effect—between TS and
thalamus volume (Table 1, p= 3 × 10−4), indicating an
association between TS genetic risk and lower thalamus
volume. Further, we found nominally significant (p < 0.05)
negative concordance between ICV and caudate volumes
with TS (Table 1). Nominally significant positive
concordance was found between the amygdala and TS.
Significant negative concordance was also identified
between the social disinhibition behaviour symptom cluster
and the thalamus (Table 2, p= 1 × 10−3) as well as mar-
ginally significant negative concordance with the accum-
bens (p= 2.3 × 10−3) and positive concordance with the
pallidum (p= 0.47 × 10−2). Significant positive con-
cordance was also identified between putamen volume and
symmetry behaviour (Table 3, p= 7 × 10−4). Evidence for
marginally significant negative concordance between this
symptom cluster and the amygdala (p= 2 × 10−3) and
positive concordance with the caudate (p= 1.7 × 10−2)
were also observed.
Replication of subcortical brain volumes and TS genetic
risk overlap using LDSR
Replication using LDSR lent trending support for an
association between TS risk and the thalamus (Table 4,
p= 5.85 × 10−2), although this was not significant. No
association between TS and pallidum volume was
observed.
Genetic variants influencing subcortical brain volumes
provide improved ability to detect TS risk variants
We performed a conditional FDR analysis, conditioning
the TS risk variants on each of the eight brain volume
GWASs (Table 5). When conditioning the TS analysis on
variants that influence ICV, rs2708146 (q= 0.046) and
rs72853320 (q= 0.035) were significantly associated with
both traits. Conditioning TS on the hippocampus also
revealed an association between rs1922786 (q= 0.001).
Each of these variants account for <1% of the variance
observed in TS, as well as in each of the associated brain
region volumes. No significant associations (q < 0.05) were
identified when conditioning TS on the other six brain
GWAS.
Table 1 SECA results for TS whole cohort
Trait 1 Trait 2 p-value pleiotropy CI pleiotropy p-value concordance CI concordance Direction
TS Intracranial volume 0.001** 0.001–0.002 0.022** 0.019–0.025 –
Accumbens 0.007** 0.006–0.009 0.054* 0.049–0.058 –
Amygdala 1 1–1 0.048** 0.044–0.053 +
Caudate 4 × 10−4*** 1 × 10−4–0.001 0.016** 0.013–0.018 –
Hippocampus 0.009** 0.007–0.011 0.07* 0.065–0.075 +
Pallidum 0.006** 0.004–0.007 0.257 0.249–0.266 –
Putamen 2 × 10−4*** 5.48 × 10−5–0.007 1 1–1 –
Thalamus 0.009** 0.008–0.012 3 × 10−4*** 1 × 10−4–0.001 –
TS Tourette’s syndrome, CI confidence interval, Bonferroni corrected p-value= 0.05/48= 1.042 × 10−3
*Trending significance (p < 0.1)
**Nominally significant (p < 0.05)
***Significant
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The conditional TDR reflects the posterior probability
that a given SNP is truly associated with the first phe-
notype (i.e. TS) given that the p-values for both pheno-
types are as small or smaller than the observed p-values.
The TDR plots show an increase in TDR associated with
increased pleiotropic enrichment in TS conditional on
nominal p-values for (i) ICV (Fig. 1) and (ii) hippocampus
volume (Fig. 2). The successive leftward shifts for
decreasing nominal p-value thresholds of both ICV and
hippocampus volumes indicate that the proportion of
SNPs with non-null effects on TS varies considerably
across various levels of association with each of these
subcortical brain volumes.
Discussion
Of the eight brain traits investigated using SECA,
associations were found between genetic risk for TS and
for lower thalamus, putamen and caudate volumes. These
Table 2 SECA results for TS social disinhibition endophenotype
Trait 1 Trait 2 p-value pleiotropy CI pleiotropy p-value concordance CI concordance Direction
TS Intracranial volume 1 1–1 1 1–1 +
Accumbens 0.31 0.301–0.319 0.002** 0.002–0.003 –
Amygdala 0.166 0.159–0.173 0.084* 0.079–0.09 –
Caudate 1 1–1 0.166 0.159–0.173 –
Hippocampus 1 1–1 0.099* 0.093–0.105 –
Pallidum 1 1–1 0.047** 0.043–0.051 +
Putamen 1 1–1 0.194 0.186–0.201 –
Thalamus 1 1–1 1 × 10−3*** 5.13e−06–0.001 –
TS Tourette’s syndrome, CI confidence interval, Bonferroni corrected p-value= 0.05/48= 1.042 × 10−3
*Trending significance (p < 0.1)
**Nominally significant (p < 0.05)
***Significant
Table 3 SECA results for TS symmetry endophenotype
Trait 1 Trait 2 p-value pleiotropy CI pleiotropy p-value concordance CI concordance Direction
TS Intracranial volume 1 1–1 0.191 0.183–0.198 –
Accumbens 0.304 0.296–0.314 0.263 0.255–0.272 –
Amygdala 0.298 0.289–0.307 0.002** 0.001–0.003 –
Caudate 0.304 0.295–0.313 0.017** 0.015–0.02 +
Hippocampus 1 1–1 0.07* 0.065–0.075 +
Pallidum 1 1–1 0.417 0.408–0.427 +
Putamen 0.313 0.304–0.322 0.001*** 0–0.001 +
Thalamus 1 1–1 1 1–1 –
TS Tourette’s syndrome, CI confidence interval, Bonferroni corrected p-value= 0.05/48= 1.042 × 10−3
*Trending significance (p < 0.1)
**Nominally significant (p < 0.05)
***Significant
Table 4 LDSR results for TS whole cohort and brain
volume overlap
Trait 1 Trait 2 rg SE 95% CI p-value
TS Intracranial volume −0.122 0.075 −0.269–0.025 0.106
Accumbens −0.428 0.582 −1.568–0.712 0.462
Amygdala – – – –
Caudate −0.037 0.087 −0.208–0.134 0.672
Hippocampus −0.015 0.097 −0.205–0.175 0.878
Pallidum −0.002 0.106 −0.21–0.206 0.983
Putamen −0.023 0.091 −0.201–0.155 0.801
Thalamus −0.227 0.12 −0.462–0.008 0.059*
TS Tourette’s syndrome, CI confidence interval, Bonferroni corrected p-value=
0.05/48= 1.042 × 10−3
*Trending significance (p < 0.1)
Mufford et al. Translational Psychiatry           (2019) 9:120 Page 5 of 10
analyses of the clinical TS phenotype were further sup-
ported by SECA findings using symptom-based pheno-
types; there was a significant association between genetic
risk for lower thalamus volume and for the social disin-




























































































































































































































































































































































































































































































































































































































Fig. 1 QQ plot of TS conditioned on ICV. The stratified true
discovery rate (TDR) plot illustrates the increase in TDR associated with
increased pleiotropic enrichment in TS conditional on nominal ICV p-
values
Fig. 2 QQ plot of TS conditioned on hippocampus volume. The
stratified true discovery rate (TDR) plot illustrates the increase in TDR
associated with increased pleiotropic enrichment in TS conditional on
nominal hippocampus volume p-values
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association between genetic risk for greater putamen
volume and for the symmetry symptom cluster. Further,
three SNPs were associated with both TS and the volumes
of the hippocampus and ICV.
Associations of genetic risk for TS with genetic risk for
alterations in thalamus and striatum volumes is consistent
with the emphasis of neuroanatomical models of TS on
these structures37,38. The thalamus has widespread pro-
jections affecting many aspects of cognition and motor
function39, and is a target for deep brain stimulation in the
treatment of refractory TS40. While greater thalamus
volumes have been reported in TS21,24, lower thalamus
volumes have been identified in paediatric patients with
TS41. The dorsal striatum is also involved in motor func-
tion42, as well as various types of learning43,44, inhibitory
control of action, and reward systems45. Evidence for both
greater46,47 and lower putamen volumes18,21,48 has been
reported in both children and adults with TS, with lower
putamen volumes reported in TS with comorbid OCD18.
Lower caudate volumes in adults and children have been
associated with TS18,48, particularly apparent in individuals
with comorbid ADHD18, and are associated with tic
severity and OCD symptoms48.
We also report a significant association between genetic
risk for lower thalamus volume and genetic risk for social
disinhibition symptoms. Social disinhibition has been
hypothesized to be an endophenotype that is relevant to
OCD, TS and ADHD, reflecting deficits in top-down
cognitive control across all of these conditions16. Given
the involvement of the thalamus in many aspects of
cognition, our findings are consistent with this
hypothesis39.
The association of genetic risk for greater putamen
volume and genetic risk for symmetry symptoms suggests
that the putamen may play a particularly important role in
symmetry behaviours. CTSC circuitry certainly plays an
important role in TS38 and it has been suggested that
more complex tics—such as those involving symmetry
behaviours—may be mediated by ventral striatal circuits49
that are also involved in OCD27,50. However, not all data
are consistent; symmetry symptoms in TS may not share a
significant degree of genetic overlap with OCD16 and
findings from neuroimaging of symmetry symptoms in
OCD have not emphasized striatal regions51,52.
The analyses here complement prior work on OCD,
where we found significant concordance between OCD
risk variants and variants that are related to greater
putamen volume (p= 8.0 × 10−4)27. In addition, the
CSTC has been implicated in both disorders38,53. Our
previous study on OCD did, however, also identify sig-
nificant concordance between greater nucleus accumbens
volume and OCD and conditional FDR only revealed
significant associations with OCD when conditioned on
putamen, amygdala and thalamus volumes27. Differences
between OCD and TS are consistent with genetic analyses
which have emphasized that despite their relatedness,
these conditions have different genetic architectures4,54.
The findings here arguably support the proposal in the
eleventh revision of the International Classification of
Diseases (ICD-11) to classify TS as both a neurodeve-
lopmental disorder and as an obsessive-compulsive rela-
ted disorder (OCRD)1,55.
The analysis here also complements previous work on
ADHD; for example, the largest subcortical brain volume
study of ADHD to date found lower putamen volumes as
well as other alterations in this disorder56. Notably,
although the putamen is also implicated in the TS sym-
metry cluster, the effect direction is opposite to that
observed in ADHD56. Additional work on neuroimaging
of children with TS may help clarify these differences.
The three variants associated with TS after conditioning
on hippocampal (rs1922786) and ICV (rs2708146 and
rs72853320) volumes have not previously been associated
with a neuropsychiatric phenotype. Both SNPs, rs2708146
and rs1922786, are intronic variants located within the
long intergenic non-protein coding RNA 1122
(LINC01122) gene on chromosome 2. The SNP,
rs72853320, is an intergenic variant closest to the RNA
U1 small nuclear 88 pseudogene (RNU1-88P) on chro-
mosome 6. To date, little is known about the function of
these genes, which are expressed in a broad range of tissue
types, including the brain (https://www.ensembl.org/
index.html, accessed on 5 April 2018). Other variants
within LINC01122 have previously been associated with
red blood cell count, mean corpuscular haemoglobin and
mean corpuscular volume in a GWAS investigating blood
cell phenotypes in the UK Biobank57. The study of blood
cell phenotypes identified a total of 2706 variants asso-
ciated with these phenotypes, located within or near genes
that are involved in pathways that have been implicated in
schizophrenia, autoimmune diseases and cardiovascular
disorders57. Further, each of the three variants identified
in the current study only accounted for <1% of the var-
iance observed in TS, as well as in each of the brain region
volumes. Better powered studies are needed to address
this issue.
Several limitations of this work should be emphasized.
First, the LDSR analysis only lends trending, but not
significant, support for the association between the tha-
lamus and TS. LDSR was further underpowered to per-
form all the tests of brain volume with the TS symptom
clusters. LDSR is ideally suited for datasets with more
than 3000 samples, which was not the case for the TS
symptom dimensions58. Estimating partitioned herit-
ability typically requires datasets with at least 5000 sam-
ples58. Approaches such as genome-wide complex trait
analysis may be more applicable in future studies with
these sample sizes, when individual-level data are
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available58. LDSR requires larger datasets compared to
SECA and cFDR as it determines genetic correlation in
one direction of effect, whereas the latter techniques use
the absolute size of effect and are able to distinguish
whether the effect allele of a SNP confers risk for both
traits or whether the effect directions are opposite for the
traits30,32,36. This also contributes to differences in the
findings obtained across these techniques. Validation in
an even larger cohort is necessary. Second, the TS GWAS
that was used in this study had low power5 and may be
susceptible to random variation. This is currently the
largest dataset available for TS and as this dataset grows,
replication studies will be possible. Third, the analysis
could be biased if overlapping participants were present in
the studies contributing to the consortia. We verified that
the cohorts as whole did not overlap and individual
overlap is, therefore, likely to be minimal. Fourth, the
ENIGMA GWASs of brain volumes contain cohorts with
healthy controls as well as patients diagnosed with neu-
ropsychiatric disorders (including anxiety, Alzheimer’s
disease, ADHD, major depression, bipolar disorder, epi-
lepsy and schizophrenia), which may bias the interpreta-
tion of our findings and how they relate to TS. However, a
direct comparison of the GWAS summary statistics
between the full ENIGMA results (including patients) and
a subset of ENIGMA results (excluding patients) showed
that they were very highly correlated (r2 > 0.99) for all
brain traits26. This suggests that the pattern of effects in
the brain volume GWAS is not likely driven by disease
status. Fifth, approximately half of the TS cohort also has
comorbid OCD. It is possible that stronger and more
specific associations may be revealed in a cohort with TS
only. Sixth, this study only investigated samples of Eur-
opean ancestry and the results are possibly only applicable
to this population. Replication studies using other popu-
lation groups are needed59. Seventh, the relationship
between gene variants influencing brain volume and
neuropsychiatric risk may be influenced by a range of
confounders, including environmental factors such as
stressors and medication effects, which may have effects
on brain volume and disease risk independent of genetics.
Discovering the pathway by which gene variants influen-
cing brain volume also create risk for TS and its symptom
clusters is therefore susceptible to influence by environ-
mental factors, which might obscure genetic relationships.
Future work on gene by environment interactions would
be useful to clarify this. However, an endeavour to find the
genetic overlap between brain volume and disorder risk
using the largest datasets to date is still worthwhile, as it
can potentially provide insights into the disorder.
In conclusion, this study implicated genetic overlap
between genetic variants influencing the volumes of the
thalamus, putamen and caudate in TS and its symptom
dimensions. Further, this study identified three SNPs
associated with TS and volumes of the hippocampus and
ICV. Indeed, these data are the first to show an overlap
between risk for genes for TS and for brain circuitry. The
correlations with putamen and thalamus volumes are
consistent with a broad range of previous neuroimaging
work. Emerging collaborations and consortia, such as
ENIGMA-TS, aim to continue to increase sample size,
which will enhance statistical power in future iterations of
this analysis. Additional work focusing on a range of other
methodologies to assess genetic overlap may also be use-
ful, following along the lines of recent work in schizo-
phrenia60–62. Such studies have used partitioning-based
heritability analysis63 and conjunction analysis64 to identify
genetic variants associated with both schizophrenia risk
and altered brain volumes. These approaches may also be
useful in future work on TS and its symptom dimensions.
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